Finally, viFSP1 (but not icFSP1) as well as FSEN1 (another inhibitor of human FSP1 developed by the Olzmann team) actively controlled the progression of human SK-MEL5 melanomas established in the popliteal lymph node of NSG mice, a therapeutic effect that could not be improved by concomitant administration of the GCLC inhibitor L-buthionine sulfoximine (L-BSO). The gene discussed is GCLC; the disease is melanoma.